Edition:
United States

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

36.01USD
1:40pm EST
Change (% chg)

$-0.65 (-1.77%)
Prev Close
$36.66
Open
$36.98
Day's High
$37.37
Day's Low
$35.73
Volume
250,618
Avg. Vol
810,867
52-wk High
$111.36
52-wk Low
$33.52

Chart for

About

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $3,878.49
Shares Outstanding(Mil.): 156.33
Dividend: --
Yield (%): --

Financials

  NKTR.OQ Industry Sector
P/E (TTM): -- 92.25 33.63
EPS (TTM): -1.40 -- --
ROI: -53.15 0.29 15.02
ROE: -- 0.94 16.60

Bristol-Myers cancer ruling hits shares after strong earnings

NEW YORK Bristol-Myers Squibb Co on Thursday said European regulators plan to recommend against approving its immunotherapy combination as an initial treatment for kidney cancer, sending shares lower even after the U.S. drugmaker reported better-than-expected quarterly profit and raised its full-year forecast.

Jul 26 2018

UPDATE 2-Bristol-Myers cancer ruling hits shares after strong earnings

NEW YORK, July 26 Bristol-Myers Squibb Co on Thursday said European regulators plan to recommend against approving its immunotherapy combination as an initial treatment for kidney cancer, sending shares lower even after the U.S. drugmaker reported better-than-expected quarterly profit and raised its full-year forecast.

Jul 26 2018

Bristol-Myers Q2 earnings rise, full-year forecast up on strong sales

NEW YORK, July 26 Bristol-Myers Squibb Co on Thursday posted better-than-expected second-quarter earnings and raised its full-year forecast on strong sales from its blockbuster cancer drug Opdivo and blood thinner Eliquis.

Jul 26 2018

Earnings vs. Estimates